Karyopharm Therapeutics (KPTI) Interest & Investment Income (2013 - 2026)

Karyopharm Therapeutics (KPTI) has 13 years of Interest & Investment Income data on file, last reported at $607000.0 in Q4 2025.

• Quarterly Interest & Investment Income fell 59.04% year-over-year to $607000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (down 62.53% YoY) and the FY2025 annual result came in at $2.8 million, down 62.53% from the prior year.
• Interest & Investment Income climbed to $607000.0 in Q4 2025, from $553000.0 in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $2.8 million in Q1 2023 to a low of $55000.0 in Q4 2021.
• A 5-year average of $1.2 million and a median of $829000.0 in 2022 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2021 — Interest & Investment Income plunged 86.11% — and 2023, when it surged 3750.0%.
• Tracing KPTI's Interest & Investment Income over 5 years: stood at $55000.0 in 2021, then jumped by 2325.45% to $1.3 million in 2022, then soared by 88.91% to $2.5 million in 2023, then tumbled by 41.19% to $1.5 million in 2024, then tumbled by 59.04% to $607000.0 in 2025.
• The last three Interest & Investment Income figures came in at $607000.0 (Q4 2025), $553000.0 (Q3 2025), and $613000.0 (Q2 2025), per Business Quant data.